Tingen Joseph S, McKinley Brian P, Rinkliff John M, Cornett Wendy R, Lucas Claiborne
Prisma Health, Department of Surgery, School of Medicine, University of South Carolina, Greenville, SC, USA.
Am Surg. 2020 Aug;86(8):1029-1031. doi: 10.1177/0003134820939903. Epub 2020 Jul 28.
Breast cancer is the most commonly diagnosed noncutaneous malignancy and remains the second leading cause of cancer deaths in women. The Savi Scout (Cianna Medical, Merit Medical Systems, Inc. South Jordan, UT) is a wireless, nonradioactive, wave reflection implant system that enables surgeons to remove targeted breast lesions. Our study aims to be the largest comparison of wire and Savi Scout localization techniques for positive margin, complication, and reoperation rates.
Single-institution retrospective review of 512 patients that had Savi Scout Surgical Guidance System breast lesion biopsy or wire localized breast biopsy from May 2017 to December 2018. A RedCaps database was created and reviewed for outcomes.
For 320 Savi scout patients, margins were positive or less than 1 mm in 18 cases (5.6%). 17 (5.3%) patients required reoperation. Surgical site occurrence was found in 7 (2.1%) patients, and 2 patients required intervention (0.6%). For 175 wire localization patients, margins were positive or less than 1 mm in 24 patients, and all required reoperation (13.7%). A surgical site occurrence was found in 13 (7.4%) patients and 5 patients required intervention (2.8%).
In our series, the Savi Scout localization system resulted in a lower rate of positive margins, reoperation, and surgical site occurrence. These data suggest that Savi Scout localization is a reasonable replacement to wire localization for breast lesions and might produce superior results.
乳腺癌是最常见的非皮肤恶性肿瘤,仍是女性癌症死亡的第二大主要原因。Savi Scout(Cianna Medical公司,Merit Medical Systems公司,犹他州南乔丹)是一种无线、无放射性的波反射植入系统,可使外科医生切除目标乳腺病变。我们的研究旨在对金属丝定位和Savi Scout定位技术在切缘阳性率、并发症及再次手术率方面进行最大规模的比较。
对2017年5月至2018年12月期间接受Savi Scout手术引导系统乳腺病变活检或金属丝定位乳腺活检的512例患者进行单机构回顾性研究。创建了一个RedCaps数据库并对结果进行了审查。
320例使用Savi Scout的患者中,18例(5.6%)切缘阳性或小于1毫米。17例(5.3%)患者需要再次手术。7例(2.1%)患者出现手术部位相关情况,2例患者需要干预(0.6%)。175例金属丝定位患者中,24例切缘阳性或小于1毫米,且均需再次手术(13.7%)。13例(7.4%)患者出现手术部位相关情况,5例患者需要干预(2.8%)。
在我们的系列研究中,Savi Scout定位系统导致切缘阳性率、再次手术率和手术部位相关情况发生率较低。这些数据表明,Savi Scout定位对于乳腺病变是金属丝定位的合理替代方法,可能会产生更好的结果。